Several Indian companies, including Larsen & Toubro, Godrej Consumer Products, and Dr Reddy’s Laboratories, are expected to record double-digit growth in their topline and bottomline figures for the March quarter due to healthy execution and strong order books. L&T’s core engineering business is expected to drive the topline with a healthy opening order book. Meanwhile, Revlimid, the cancer drug, is expected to have contributed significantly to growth in Dr Reddy’s US sales.
FPIs continue to invest; inject Rs 14,167 cr in equities in May
Foreign investors continue to show confidence in the country’s equity market, infusing Rs 14,167 crore so far this month, largely driven by favourable global cues
May 11, 2025